Skip to content
Screener

EyePoint, Inc. EYPT Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.25B-11.7%
Regenxbio logo
RegenxbioRGNX
$22.7M+132%
KLR
Kalaris TherapeuticsKLRS
-$10.91M-7.0%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-$18.81M+7.7%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Net loss per share:
Basic and diluted$(1.09)$(0.85)$(2.08)$(1.50)
Weighted average common shares outstanding:
Basic and diluted86,54369,92686,27269,847
Net loss$(94,470)$(59,426)$(179,302)$(104,621)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities(9)(91)(168)(196)
Comprehensive income (loss)$(94,479)$(59,517)$(179,470)$(104,817)

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
EyePoint, Inc. (EYPT) reported comprehensive income (loss), net of tax, attributable to parent of -$94.48M in Q2 2026.
How has EyePoint, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
EyePoint, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 58.7% year-over-year, from -$59.52M to -$94.48M.
What is the long-term trend for EyePoint, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), EyePoint, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 41.2% compound annual growth rate (CAGR), from -$58.42M to -$232.03M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
Captures the total change in equity from non-owner sources, including net income and other comprehensive income items like unrealized gains or losses. This provides a holistic view of the company's financial performance beyond standard accounting profit. It is a key measure for assessing total value creation or erosion over a period.

Ask your AI about EyePoint, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude